Injectable drug delivery is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024.

DALLAS, TEXAS, UNITED STATES, June 16, 2017 /EINPresswire.com/ -- Injectable drug delivery is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User (Hospitals & Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa) – Industry Trends and Forecast to 2024

The global injectable drug delivery market is segmented on the basis of type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography.

Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Ask for Sample of the report: http://databridgemarketresearch.com/request-a-sample/?chalet=Global%20Injectable%20Drug%20Delivery%20Market

Segmentation:

By Type:
1. Devices
• Conventional Injection
• Self-Injection
2. Formulations
• Conventional Drug Delivery,
• Noble Drug Delivery,
• Long Acting Injection Formulations
By Applications:
• Autoimmune Diseases
• Hormonal Disorders
• Orphan Diseases
• Oncology
By Usage Pattern:
• Curative Care
• Immunizations
By Mode of Administration:
• Skin
• Circulatory
• Organs
• Central Nervous System
By End User:
• Hospitals & Clinics
• Home Care Settings
• Research Laboratories
• Pharma & Biotech Companies
By Geography:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East Africa


Some of the major factors driving the market for injectable drug delivery market are increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain).

Read More on the market trends of Global Injectable Drug Delivery Market: http://databridgemarketresearch.com/global-injectable-drug-delivery-market-is-growing-at-a-significant-rate-in-the-forecast-period-2017-2024/

The major players in the injectable drug delivery are Baxter International, Inc., Becton Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceuticals Industries Ltd., Bespak, Antares Pharma, Elcam Medical, Haselmeier, Mylan N.V., Novo Nordisk, Owen Mumford Ltd,Sanofi, West Pharmaceutical Services, Inc, Ypsomed Holding AG.

Some Recent Developments:

•Becton, Dickinson and Company
1.In August 2016, BD (Becton, Dickinson and Company), a leading global medical technology company, announced that it has received U.S. Food and Drug Administration (FDA) clearance for its new syringe for patients using Humulin R U-500 insulin vials.

•Pfizer
1.In March 2017, Pfizer Inc. and Merck announced the FDA approval of BAVENCIO (avelumab) Injection, for intravenous use which is used for the treatment of adults and pediatric patients and with metastatic Merkel cell carcinoma (mMCC)

Purchase Request: http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/

Table Of Contents:

1. INTRODUCTION
1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE
2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.1. OVERVIEW
5.2. INJECTABLE DRUG DELIVERY DEVICES
5.3. INJECTABLE DRUG DELIVERY FORMULATIONS
6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. CONVENTIONAL INJECTION DEVICES
6.3. SELF INJECTION DEVICES
6.3.1. NEEDLE FREE INJECTOR
7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
7.1. OVERVIEW
7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3. NOVEL DRUG DELIVERY FORMULATIONS
8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS
8.1. OVERVIEW
8.2. AUTOIMMUNE DISEASES
8.3. HORMONAL DISORDER
8.4. ORPHAN DISEASES
8.5. ONCOLOGY
8.6. OTHERS
9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
12.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS
CHAPTER BY COUNTRY
12.1.2. EUROPE
12.1.3. ASIA-PACIFIC (APAC)
12.1.4. LATIN AMERICA
12.1.5. MIDDLE EAST AND AFRICA
12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.7. MERGERS & ACQUISITIONS
13.8. NEW PRODUCT DEVELOPMENT & APPROVALS
13.9. EXPANSIONS
13.10. REGULATORY CHANGES
13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
14.1. BAXTER INTERNATIONAL, INC.
14.2. BECTON, DICKINSON AND COMPANY
14.3. GERRESHEIMER, AG
14.4. PFIZER, INC
14.5. SCHOTT AG
14.6. ALKERMES PLC
14.7. ELI LILLY AND COMPANY
14.8. SANDOZ
14.9. TERUMO CORPORATION
14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD
15. APPENDIX
15.1. RELATED REPORTS
15.2. CUSTOMIZABLE OPTIONS
15.3. SOURCE SHEET
15.4. BIBLIOGRAPHY
16. ABOUT DATA BRIDGE MARKET RESEARCH

Vishal Dwivedi
Data Bridge Market Research Private Ltd.
+1-888-387-2818
email us here